Carmen LEFAUCHEUR, MD, PhD

Nephrology and Kidney Transplantation Department
Saint-Louis Hospital
1 avenue Claude Vellefaux
75475 Paris Cedex 10, France
Phone: (+33) 6 76 60 49 46
Email: carmen.lefaucheur@wanadoo.fr

Current Position :

- **Professor of Nephrology**, Université Paris Cité
- **Head of the Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital** in Paris
- **Scientific Director & Co-Head of Paris Expertise Center for Organ Transplantation**
- **Medical Director of Paris Institute for Transplantation & Organ Regeneration** (PITOR)
- **Coordinator of the FHU-Apollo AP-HP Nord Université Paris Cité** "Personalized medicine in chronic cardiovascular, respiratory, renal diseases and organ transplantation"
- **Member of the Scientific Committee of the French Biomedicine Agency**
- **Member of the Board of Trustees and of the Scientific Committee of Banff Classification for Allograft Pathology**
- **Member of ESOT SPC 2023** (European Society of Organ Transplantation Scientific Programme Committee)
- **Member of the European Society of Transplantation (ESOT) Education Committee**
- **Member of the American Society of Transplantation (AST) Research Committee**

Education:

1994	M.D.	University "Iuliu Hatieganu", Cluj Napoca, Romania
2002	M.S.C.E.	Paris Diderot University
2004	Specialist in Nephrology	Paris Descartes University
2005	Specialist in Clinical Immunology	Paris Descartes University
2013	Ph.D in Biology and Biotechnology	Paris Diderot University
2014	HDR Accreditation to direct Research	Paris Diderot University
2021	School of Management, EMAMH, ranked first in the 43rd promotion	Public Hospitals of Paris (AP-HP) and Ecole Supérieure Nationale des Mines de Paris

Postgraduate Training and Fellowship Appointments:

1998-2004	Nephrology Internship and Residency, Public Hospitals of Paris (AP-HP)
2004-2006	Fellow, Nephrology, Georges Pompidou European Hospital, Paris, Paris Descartes University
2010-2012	Ph.D in Biology and Biotechnology, Paris Descartes University, INSERM UMR-S 940, Immunology-Therapeutic Targets ("Role of Anti-HLA Antibodies in Organ Transplantation")
2012-2013	Post-Doctoral Fellow, Department of Epidemiology and Biostatistics; PARCC Cardiovascular Research Center of Paris.
2013-2014	Post-Doctoral Fellow, Genetic applied Center ATAGC University of Alberta, Applied Genomic center ATAGC Kidney Transplant Department

Faculty and Hospital Appointments:

2007-2011	Full time Attending Physician, Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital, Paris

2015-present	Nephrologist, Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital, Paris
2015-present	Professor of Nephrology, Paris Diderot University/Université Paris Cité
2015-present	Scientific Director of Paris Translational Research Center for Organ Transplantation, INSERM UMR-S970, INSERM UMR-S976PARCC
2017-2019	Medical Director, Ambulatory Transplantation Care, Saint-Louis Hospital, Paris
2018-present	Coordinator of the Hospital and University Federation FHU-Apollo AP-HP Nord Université Paris Cité "Personalized medicine in chronic cardiovascular, respiratory, renal diseases and organ transplantation"
2022-present	Head of the Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital in Paris and Head of the Kidney and Pancreas Transplant program
2023-present	Medical Director of Paris Institute for Transplantation & Organ Regeneration (PITOR)

Awards and Honors:

2023	Paul I. Terasaki Clinical Science Award, American Society for Histocompatibility & Immunogenetics (ASHI)
2023	StrongerTogether PRO Award for the Transplant Institute with the best average score from European Society of Organ Transplantation (ESOT)
2021	StrongerTogether PRO Award for the Transplant Institute with the best average score from European Society of Organ Transplantation (ESOT)
2019	European Society of Organ Transplantation Award
2019	Prix de la Recherche 2019, CSL Behring
2019	PEDR by National University Council and "Université de Paris"
2017	StrongerTogether PRO Award for the Transplant Institute with the best average score from European Society of Organ Transplantation (ESOT)
2017	Best Clinical Research from the European Society of Organ Transplantation (ESOT) Award
2014	Sorbonne University of Paris, Louis Forest / Kuntz-Chagniot Award (Prix de la Chancellerie des Universités de Paris)
2013	Ph.D very honorable distinction with congratulation from the jury from Paris Diderot University
2012	Transplant Immunology Award, Berne
2010	International Transplant Society New Key Opinion Leader Award
2002	National Academy of Medicine (Académie Nationale de Médecine) Award

Grants:

2021-2026	RO1 Grant: Biomarkers and digital pathology (9 000 000€) (Role in grant : Coordinator and PI)
2020-2023	NIH RO01 AI 130010 (Role in grant : PI)
2020-2025	FHU Nord Apollo: Cardiovasculaire/Pneumo/Néphro/Maladies systémiques et Transplantation d'organes (6 000 000€) (Role in grant : coordinator)
2018-2025	MSDAVENIR: Artificial intelligence for personalized medicine in organ transplantation (2 500 000€) (Role in grant : coordinator and PI)
2018-2020	NIH Post-Doctoral Award T32 Interdisciplinary Training in Transplantation Biology
2017-2023	European Research Council H2020 SC1-PM-02-2017 : EUTRAIN project (6 539 000 €) (Role in grant: co-coordinator and PI) Coordinating Investigator of NCT03652402 "Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN"
2017-2023	French National Research Agency, "Future Investments", RHU 2017: KTD-Innov project (8 794 510 €) (Role in grant: PI) Coordinating Investigator of NCT03582436 "Prospective KTD-Innov Cohort of Kidney Transplant Patients"

Memberships in Professional, Scientific Societies and Institutional Committees:

2023-present	Member of the Scientific Committee of the French Biomedicine
2023-present	Mentor for the ESOT Mentorship Program
2022-present	Member of the Board of Trustees and of the Scientific Committee of Banff Classification for Allograft Pathology
2021-present	Member of the Scientific Program Committee of ESOT
2021-present	Member of AST Research Committee
2019-present	Coordinator of the national French protocol RTU for Complement Inhibitors in Antibody-mediated rejection refractory to standard of care treatment (ANSM 2019)
2018-present	Member of the STAR working group for recommendations and guidelines of American Society for Histocompatibility and Immunogenetics and American Society of Transplantation (ASHI and AST)
2016-2021	Executive Member for Consensus Guidelines for Diagnosis Treatment of Antibody-mediated Rejection by the International Transplant Society
2015-2019	Scientific Committee of the International Classification of Allograft Rejection
2016-present	European Society of Organ Transplantation (Member)
2016-present	American Society of Transplantation (Member)
2015-present	Expert for the French Biomedicine Agency (Agence de la Biomédecine)
2015-present	Expert for International Transplantation Society Consensus Conference on Immunosuppression in Transplantation Trials
2013-present	Francophone Society of Organ Transplantation (Member)
2013-2015	Scientific board of Consensus guidelines on the testing and clinical management issues associated with HLA antibodies in organ transplantation, by the Francophone Society of Transplantation and the French Society of Immunohistocompatibility
2012-present	Scientific board of the DIVAT network (Données Informatisées et Validées en Transplantation / computerized and validated data in transplantation)

Organizing Roles in Scientific Meetings and Editorial Positions:

2022-2024	Organizer and Scientific Director of the Banff International Allograft Pathology Conference, Paris 2024
2021-2023	ESOT SPC Member, ESOT Congress, Athens 2023
2019-2022	Chair of ESOT EU-TRAIN Educational Workshops, Barcelona 2019, Berlin 2020, Paris 2022
2021	Chair of the Symposium EU-TRAIN ESOT, Milano, Italy
2017-present	Session Moderator & Abstract Reviewer for ESOT, ATC, ASHI,ERA-EDTA, TTS Congresses & for the International Conference of Allograft Rejection Classification
2019	Chair of the Symposium EU-TRAIN ESOT, Copenhagen, Denmark
2018	Chair of ESOT workshop on desensitization, Paris, France
2018	Chair of the Asian Kidney Transplant Summit, Xi'An, China
2015-present	Ad Hoc Reviewer, New England Journal of Medicine, The Lancet, Kidney International, Journal of the American Society of Nephrology, American Journal of Transplantation, Transplantation

Lectures by Invitation and Oral Communication in the Main International Congress:

Since 2015, the team I lead is actively present in all major European and International Congress. For example : 21 oral communications in the ESOT 2019, 18 in the ESOT 2021, 16 oral communications in ATC 2019, etc..).

Sept, 2023	"Crossing DSA barriers to transplant today", European Society of Organ Transplantation (ESOT), Athènes, Grèce
Sept, 2023	"Biomarkers : the magic key for early detection of changes occurring in the graft ?", European Society of Organ Transplantation (ESOT), Athènes, Grèce
Sept, 2023	AI in transplantation: AI empowered algorithms in clinical practice, European Society of Organ Transplantation (ESOT), Athènes, Grèce

Sept, 2023	"Treatment of Antibody Mediated Rejection", European Society of Organ Transplantation (ESOT), Athènes, Grèce
Sept, 2023	What's NEW? Importance of early detection of changes occurring in the graft, European Society of Organ Transplantation (ESOT), Athènes, Grèce
Mar, 2023	Fifth International Deimmunization Expert Meeting, Bruxelles, Belgium
Nov, 2022	ESOT TLJ 3.0 Consensus Conference for ESOT Guidelines on immunological monitoring in kidney transplantation, Prague
Jun, 2022	"Non-HLA Antibodies in organ transplantation", Banff International Classification for Rejection meeting, Banff, Canada
Mar, 2022	"Interactive Workshop on Perspective on Non-HLA antibodies" American Society of Histocompatibility Immunogenetics (ASHI) & International Pediatric Transplant Association (IPTA), Prague, République Tchèque
Feb, 2022	"Clinical recommendations for post-transplant monitoring: a STAR consensus", Cutting Edge in Organ Transplantation Meeting, American Society of Transplantation, Phoenix, USA
Oct, 2021	"Sensitization in Transplantation : assessment of risk, American Society of Histocompatibility Immunogenetics (ASHI), webimar
Sep, 2021	"The Digital Transformation – 2021 Tools", European Society of Organ Transplantation (ESOT), Milan, Italie
Jun, 2021	"Clinical Recommendations for Immunomonitoring in Organ Transplantation", Assessment of risk (STAR) 2021 Working Group Meeting, Web Meeting
May, 2021	"Molecular Diagnostics Changes. Made in the Banff Classification ?", Societat Catalana de Trasplantament 2021, Barcelone, Espagne
Apr, 2021	"Precision Diagnosis in Kidney Transplantation", Cedars-Sinaï Medical Center and UCLA, Web Presentation
Sep, 2020	"What are the Data to Support the Molecular Diagnostics Changes. Made in the 2019 Banff Classification?", International Congress of The Transplantation Society, Web Presentation
Sep, 2020	"Testing for HLA antibody attributes should be common practice", International Congress of The Transplantation Society, Web Presentation
Mar, 2020	"The changing landscape of HLA and non-HLA antibodies in kidney transplant", World Congress of Nephrology, Abu Dhabi, Emirats Arabes Unis
Feb, 2020	"2019 : Consensus for Antibody-Mediated Rejection Treatment", Société Espagnole de Transplantation, Madrid, Espagne
Nov, 2019	"Gene Expression Profiling and Histologic and Noninvasive Biomarkers in Antibody-Mediated Rejection", American Society of Nephrology, Washington, USA (L)
Sep, 2019	"The EU-TRAIN Consortium", European Society of Organ Transplantation, Copenhagen, Denmark (L)
Sep, 2019	"Transplanting Highly Sensitised Patients: Current Approaches to Desensitisation", European Society of Organ Transplantation, Copenhagen, Denmark (L)
Sep, 2019	International Transplantation Society Consensus Update, Banff and ASHI, Pittsburgh, USA (L)
Jun, 2019	"Moving towards personalized medicine in SOT" (L) and 5 Oral Communications, ERA-EDTA, Budapest, Hungary
Jun, 2019	"Anti-Angiotensin II Type 1-Receptor Antibodies for Risk Stratification in Organ Transplantation", and 10 Oral Communications, American Transplant Congress, Boston, USA
Feb, 2019	"Complement in antibody-mediated injury following organ transplantation: The path towards personalized therapy", Cutting Edge of Transplantation, American Society of Transplantation, Phoenix, USA (L)
Feb, 2019	Invited speaker by Starzl Transplant Institute, Personnalized Medicine in Organ Transplantation, Pittsburgh, USA
Nov, 2018	"Update in immunology risk assessment to avoid rejection", Clinical Transplantation Update Day, Euromeeting, Barcelona, Spain (L)
Sep, 2018	"iTransplant: Artificial Intelligence for Personalized Medicine", "Multidimensional Approach to HLA Antibodies: Moving towards personalized medicine in SOT", Croatian Transplantation School by ERA-EDTA Association, Dubrovnik, Croatia (L)

Sep, 2018	"Chronic T-cell mediated rejection" Universitätsspital, Basel, Switzerland (L)
Jul, 2018	" Anti-Angiotensin II Type 1-Receptor Antibodies Are Associated With A Distinct Pattern of Antibody-Mediated Rejection", International Congress of The Transplantation Society, Madrid, Spain (CO)
	"C1q-binding HLA DSA for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard-of-Care Treatment", International Congress of The Transplantation Society, Madrid, Spain (CO)
Jun, 2018	"Anti-Angiotensin II Type 1-Receptor Antibodies Are Associated With A Distinct Pattern of Antibody-Mediated Rejection", American Transplant Congress, Seattle, USA (CO)
	"Inflammation in Scarred Areas (i-IF/TA): Defining the Response to Standard Treatment of T Cell-Mediated Rejection in Kidney Recipients", American Transplant Congress, Seattle, USA (CO)
May, 2018	"Antibody-Mediated Rejection: Current Concepts And Future Direction", Asian Kidney Transplant Summit, University of Shanghai, China
	"ABMR Treatment in 2018: induction therapies and therapeutic strategies", Asian Kidney Transplant Summit, University of Xi'An, China (L)
Dec, 2017	"Les DSA au Coeur des débats", Congrès de la Société Francophone de Transplantation, La Rochelle, France (L)
Nov, 2017	"Role of HLA antibodies in organ transplantation: Improving diagnostic and risk stratification sys", Intercontinental Kidney Transplant Immunosuppression Masterclass, Singapore (L)
Oct, 2017	"Histoire naturelle du rejet vasculaire, place des inhibiteurs du complément en transplantation",Congrès de la Société de Néphrologie, Nice, France (L)
Oct, 2017	"Multidimensional Approach of Antibodies: Moving for personalized medicine", Brazilian Society of Histocompatibility and Brazilian Transplant Congress Joint Scientific Meeting, Brazil (L)
Sep, 2017	"Molecular microscope strategy for allograft diagnostic to inform therapeutic decision making", European Society of Organ Transplantation, Barcelona, Spain (L)
	"Specific Gene Expression Signature of C'-Activating Donor-Specific Anti-HLA Antibodies in Kidney Allografts", European Society of Organ Transplantation, Barcelona, Spain (CO)
	"Complement-activating anti-HLA antibodies: Specific Histo-Molecular Rejection Phenotype For Complement-Targeting Therapy", European Society of Organ Transplantation, Barcelona, Spain (CO)
Sep, 2017	"Complement-activating anti-HLA antibodies: Specific Histo-Molecular Rejection Phenotype For Complement-Targeting Therapy", American Society for Histocompatibility and Immunogenetics, San-Francisco, USA (L)
Jun, 2017	"Role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials", Workshop China Tour, University of Guangzhou, China (L)
	"Role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials", Workshop China Tour, University of Changchun, China (L)
May, 2017	"Multidimensional Approach of Antibodies: Moving for personalized medicine", American Transplant Congress, Chicago, USA (L)
	"Specific Gene Expression Signature of C'-Activating Donor-Specific Anti-HLA Antibodies in Kidney Allografts", American Transplant Congress, Chicago, USA (CO)
	"Complement-activating anti-HLA antibodies: Specific Histo-Molecular Rejection Phenotype for Complement-Targeting Therapy", American Transplant Congress, Chicago, USA (CO)
May, 2017	"Role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials", International Pediatric Transplant Association, Barcelona, Spain (L)
May, 2017	"Classification and Risk Scores in Antibody-Mediated Rejection", University of Medicine – Charité, Berlin, Germany (L)
Mar, 2017	"The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials", Banff Foundation for Allograft Pathology and the STC Joint Scientific Meeting, Barcelona, Spain (L)
	"Multidimensional Approach of Antibodies: Moving for personalized medicine", Banff Foundation for Allograft Pathology and the STC Joint Scientific Meeting, Barcelona, Spain (L)

Feb, 2017	"Multidimensional Approach of Antibodies: Moving for personalized medicine", Cutting Edge of Transplantation, American Society of Transplantation, Phoenix, USA (L)
Dec, 2016	"The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials", Congrès de la Société Francophone de Transplantation, Liège, Belgium (CO)
Nov, 2016	"Multidimensional Approach of Antibodies", National Institutes of Health Meeting, Birmingham, Great Britain, (L)
Sep, 2016	"Multidimensional Approach of Antibodies", 12th International Congress on Lung Transplantation, Paris, France (L)
Aug, 2016	"Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of ABMR in Kidney Transplantation", International Congress of The Transplantation Society, Hong Kong, (CO)
	"C1-Inhibitor in Acute Antibody-Mediated Rejection Non-Responsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study", International Congress of The Transplantation Society, Hong Kong, (CO)
	"Effect of Complement Inhibition Therapy (Eculizumab) in Patients With C1q-Binding Donor-Specific Anti-HLA Antibodies: a Molecular Appraisal", International Congress of The Transplantation Society, Hong Kong, (CO)
Jun, 2016	"C1-Inhibitor in Acute Antibody-Mediated Rejection Non-Responsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study", American Transplant Congress, Boston, USA (CO)
	"Effect of Complement Inhibition Therapy (Eculizumab) in Patients With C1q-Binding Donor-Specific Anti-HLA Antibodies: a Molecular Appraisal", American Transplant Congress, Boston, USA (CO)
Nov, 2015	"Rejection in high-risk patients", Clinical Transplantation Update Day, Parma, Italia (L)
Oct, 2015	"Endothelium and Transplant Arteriosclerosis from Kidney to Heart: Epidemiologic Demonstration", Banff Foundation for Allograft Pathology, Vancouver, Canada (L)
	"Anti HLA DSA IgG Subclasses and Allograft Injury", Banff Foundation for Allograft Pathology, Vancouver, Canada (L)
Sep, 2015	"The DSA phenotype", European Society of Organ Transplantation, Brussels, Belgium (CO)
Sep, 2015	"Design clinical trial with a surrogate end-point for graft loss at 3 to 5 years for: prevention trial for development of de novo DSA and/or intervention trial for patients that have developed dnDSA", Consensus Conference on IS Trials, The Transplant Society, Arlington, USA (L)
Sep, 2015	"Unresolved issues in the pathogenesis of ABMR", International Workshop, Heidelberg, Germany (L)
Aug, 2015	"Role of Complement in Antibody Mediated Rejection", Congress of the Asian Society of Transplantation, Singapore (L)
	"Molecular Microscope in ABMR", Congress of the Asian Society of Transplantation, Singapore (L)
	"Anti-HLA Antibodies: The Next Enemy", Congress of the Asian Society of Transplantation, Singapore (L)
Jun, 2015	"Bridging the Gap Between Antibodies and Allograft Injury" , Workshop China Tour, University of Guangzhou, China (L)
Apr, 2015	"Bridging the Gap Between Antibodies and Allograft Injury", European Immunogenetics and Histocompatibility Conference, Genève, Switzerland (L)

Bibliography :

117 Research Publications, peer reviewed, 5 among the 1 % of the most cited articles in Medicine
(* co first or co-last author)
The 20 most significant:

Yoo D, Goutaudier V, Divard G, Gueguen J, Astor BC, Aubert O, Raynaud M, Demir Z, Hogan J, Weng P, Smith J, Garro R, Warady BA, Zahr RS, Sablik M, Twombley K, Couzi L, Berney T, Boyer O, Duong-Van-Huyen JP, Giral M, Alsadi A, Gourraud PA, Morelon E, Le Quintrec M, Brouard S, Legendre C, Anglicheau D, Villard J, Zhong W, Kamar N, Bestard O, Djamali A, Budde K, Haas M, **Lefaucheur C**, Rabant M, Loupy A. An automated histological classification system for precision diagnostics of kidney allografts. Nat Med. 2023 May 4. doi: 10.1038/s41591-023-02323-6. Online ahead of print. PMID: 37142762

Lefaucheur C, Louis K, Morris AB, Taupin JL, Nickerson P, Tambur AR, Gebel HM, Reed EF; STAR 2022 Working Group. Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. Am J Transplant. 2023 Jan;23(1):115-132. doi: 10.1016/j.ajt.2022.11.013. Epub 2023 Jan 11. PMID: 36695614

Divard G, Raynaud M, Tatapudi VS, Abdalla B, Bailly E, Assayag M, Binois Y, Cohen R, Zhang H, Ulloa C, Linhares K, Tedesco HS, Legendre C, Jouven X, Montgomery RA, **Lefaucheur C** *, Aubert O *, Loupy A *. Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure. Commun Med (Lond). 2022 Nov 23;2(1):150. doi: 10.1038/s43856-022-00201-9. PMID: 36418380

Louis K, Fadakar P, Macedo C, Yamada M, Lucas M, Gu X, Zeevi A, Randhawa P, **Lefaucheur C** *. Concomitant loss of regulatory T and B cells is a distinguishing immune feature of antibody-mediated rejection in kidney transplantation. Kidney Int. 2022 May;101(5):1003-1016. doi: 10.1016/j.kint.2021.12.027. Epub 2022 Jan 26. PMID: 35090879

Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, Dürr M, Domínguez-Gil B, Coll E, Da Silva MI, Sallinen V, Lemström K, Midtvedt K, Ulloa C, Immer F, Weissenbacher A, Vallant N, Basic-Jukic N, Tanabe K, Papatheodoridis G, Menoudakou G, Torres M, Soratti C, Hansen Krogh D, **Lefaucheur C**, Ferreira G, Silva HT Jr, Hartell D, Forsythe J, Mumford L, Reese PP, Kerbaul F, Jacquelinet C, Vogelaar S, Papalois V, Loupy A. COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health. 2021 Oct;6(10):e709-e719. doi: 10.1016/S2468-2667(21)00200-0. Epub 2021 Aug 30. PMID: 34474014

Louis K, Bailly E, Macedo C, Lau L, Ramaswami B, Chang A, Chandran U, Landsittel D, Gu X, Chalasani G, Zeevi A, Randhawa P, Singh H, Metes D, **Lefaucheur C** *. T-bet+CD27+CD21- B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants. JCI Insight. 2021 Jun 22;6(12):e148881. doi: 10.1172/jci.insight.148881. PMID: 34032636

Loupy A, Aubert O, Naesens M, Bouatou Y, Jackson A, Viglietti D, Giral M, et al. & **Lefaucheur C**. Allograft Loss Risk Prediction Score in Kidney Transplant Recipients: An International Derivation and Validation Study. BMJ. 2019 Sep 17;366:l4923. PMID: 31530561

Aubert O, Reese P, Audry B, Bouatou Y, Raynaud M, Viglietti D, Jacquelinet C, **Lefaucheur C**, Loupy A. Kidney transplant outcomes and organ acceptance practice patterns: nationwide analyses of the US and France. JAMA. 2019 Aug 26. doi: 10.1001/jamainternmed.2019.2322. PMID: 31449299

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int. 2019 Jul;96(1):189-201. PMID: 31005275

Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen JP, Rabant M, Aubert O, Taupin JL, Glotz D, Legendre C, Loupy A, **Lefaucheur C**. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. Am J Transplant. 2019 Jul;19(7):1972-1988. PMID: 30748089

Loupy A and **Lefaucheur C**. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med. 2018 Sep 20;379(12):1150-1160. PMID: 30231232

Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, **Lefaucheur C**. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int. 2018 Oct;94(4):773-787. PMID: 29801667

Viglietti D, Loupy A, Aubert O, Bestard O, Van Huyen JD, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, **Lefaucheur C**. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. J Am Soc Nephrol. 2018 Feb;29(2):606-619. PMID: 29255058

Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, Louis K, Glotz D, Legendre C, Duong Van Huyen JP, Loupy A. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant. 2018 Feb;18(2):377-390. PMID: 29086461

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. J Am Soc Nephrol. 2018 Feb;29(2):620-635. PMID: 29042454

Viglietti D, Loupy A, Vernerey D, Bentljewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, **Lefaucheur C**. Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol. 2017 Feb;28(2):702-715. PMID: 27493255

Lefaucheur C, Viglietti D, Bentljewski C, Duong van Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A. IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol. 2016 Jan;27(1):293-304. PMID: 26293822

Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Duong-Van-Huyen JP, Eladari D, Empana JP, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, **Lefaucheur C**, Loupy A. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ. 2015 Jul 31;351:h3557. PMID: 26232393

Loupy A, Vernerey D, Viglietti D, Aubert O, Duong Van Huyen JP, Empana JP, Bruneval P, Glotz D, Legendre C, Jouven X, **Lefaucheur C**. Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies. Circ Res. 2015 Aug 14;117(5):470-82. PMID: 26056252

Lefaucheur C*, Loupy A*, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013 Sep 26;369(13):1215-26. PMID: 24066742 (* Co-first Author)

Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013 Jan 26;381(9863):313-9. PMID: 23182298